NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Excuse me: Same point, but DCVax-l with significant residual disease (10.6% at risk) uncharacteristically (but logically) essentially tied DC-Vax-l with minimal residual disease (10.9% at risk) regarding five year survival.

That disproves Ex’s point.

Note:

Remember, the easy tumors to remove are not the ones DCVax-l works best on. Instead, mesenchymal tumors are more infiltrative and tend to jut out in various places. This is probably why you still see many partial resections in the DCVax-l trial. — flipper